IHE
iShares U.S. Pharmaceuticals ETF
NYSEArcaUSDETF / FUND
DELAYED
Neutral
+10/100
Last price
98.34
▲ 0.12 (0.12%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
98.22
Day high
98.98
Day low
97.19
Volume
327.91K
Market cap
—
P/E (TTM)
25.75
52W range
72.94 – 108.66
Trailing performance
Returnvs SPY
1W
-3.83%
-5.8%
1M
-6.06%
-7.2%
3M
-3.94%
-8.5%
6M
+14.36%
-3.8%
YTD
+15.93%
+1.7%
1Y
+30.06%
+13.6%
3Y
+66.70%
-15.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Top holdings
| Symbol | Name | Weight | |
|---|---|---|---|
| LLY | Eli Lilly and Co | 23.51% | |
| JNJ | Johnson & Johnson | 22.64% | |
| PFE | Pfizer Inc | 4.69% | |
| VTRS | Viatris Inc | 4.55% | |
| MRK | Merck & Co Inc | 4.50% | |
| BMY | Bristol-Myers Squibb Co | 4.43% | |
| RPRX | Royalty Pharma PLC Class A | 4.40% | |
| ZTS | Zoetis Inc Class A | 4.35% | |
| JAZZ | Jazz Pharmaceuticals PLC | 3.36% | |
| ELAN | Elanco Animal Health Inc | 2.50% |
Sector exposure
Healthcare
100.00%
Fund profile
Fund familyiShares
CategoryHealth
Legal typeExchange Traded Fund
Expense ratio0.37%
Turnover29.0%
Total net assets$106.46M
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IHE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E25.75
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Options analytics
Put / call volume
0.27
Call-heavy session
Put / call open interest
0.33
Positioning, not flow
Max pain
87.00
-11.5% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
-28.0%
Calls bid over puts
Call volume
11
Contracts, this expiry
Put volume
3
Contracts, this expiry
Heaviest call OI
110.00
2 contracts
Heaviest put OI
94.00
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
100.64
-2.28% from price
SMA 20
101.19
-2.82% from price
SMA 50
102.87
-4.40% from price
SMA 100
99.22
-0.88% from price
SMA 200
93.27
+5.43% from price
EMA 12
100.36
-2.01% from price
EMA 26
101.45
-3.07% from price
EMA 50
101.41
-3.03% from price
RSI (14)
35.1
Neutral
MACD (12,26,9)
-1.09
Hist -0.43
ATR (14)
1.66
1.68% of price
Realised vol 30D
13.9%
Annualised
Bollinger upper
104.15
20, 2σ
Bollinger lower
98.23
20, 2σ
50 / 200 cross
Golden
102.87 vs 93.27
Trend bias
Above 200
+5.43%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.37
Less volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
13.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-9.2%
Peak to trough
Max drawdown 5Y
-17.4%
Peak to trough
ATR 14
1.66
1.68% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Execution of Pharma Tariffs Brings These ETFs Into Focus
Zacks · 20h ago
Eli Lilly Scores FDA Win for Pancreatic Cancer Drug. How It’s Moving Beyond GLP-1s.
Barrons.com · 2d ago
The Midterms Are Coming. Tech Stocks May Have a Problem.
Barrons.com · 14d ago
Why One of the Last Eli Lilly Holdouts Just Upgraded the Stock to Buy
Barrons.com · 22d ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Zacks · 22d ago
Moderna's 177% Surge Powers a Broad Biotech Rally
etf.com · 48d ago
Healthcare ETFs Are Looking Up: Here's Why
Zacks · 49d ago
Jim Cramer Says One Group of Stocks is ‘So Hated’ Right Now. Is it Time to Buy?
24/7 Wall St. · 51d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.